Organigram Global (OGI) Short term Debt (2018 - 2023)

Organigram Global (OGI) posted quarterly Short term Debt of $56690.7 for Q3 2023, down 8.74% quarter-over-quarter from $62121.4 in Q3 2022.

Organigram Global (OGI) Short term Debt (2018 - 2023) Analysis & Trends

Organigram Global (OGI) has reported Short term Debt for 6 consecutive years, with $56690.7 the latest figure, recorded in Q3 2023.

In Q3 2023, Short term Debt changed N/A year-over-year to $56690.7; the TTM figure through Sep 2023 stood at $56690.7 (changed N/A YoY), while the FY2023 annual figure was $56690.7, changed N/A from the prior year.
Short term Debt declined to $56690.7 in Q3 2023 per OGI's latest filing, from $62121.4 in the prior quarter.
Across five years, Short term Debt topped out at $84.9 million in Q1 2020 and bottomed at $56690.7 in Q3 2023.
Historically, Short term Debt has averaged $14.2 million across 5 years, with a median of $2.5 million in 2019.
Annual changes were most pronounced in 2019 — Short term Debt soared 725.45% — and 2021, when it slumped 99.87%.
Organigram Global's Short term Debt stood at $2.7 million in 2019, then surged by 2203.75% to $61.1 million in 2020, then plunged by 99.87% to $80000.0 in 2021, then dropped by 22.35% to $62121.4 in 2022, then slipped by 8.74% to $56690.7 in 2023.
Business Quant data shows OGI's Short term Debt at $56690.7 in Q3 2023, $62121.4 in Q3 2022, and $80000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Organigram Global	150.66 Mn	150.54 Mn	28.97 Mn

Download Data